NextGen cell-based immunotherapies in cancer and other immune disorders

Camillia S Azimi; Qizhi Tang; Kole T Roybal; Jeffrey A Bluestone

doi:10.1016/j.coi.2019.03.007

NextGen cell-based immunotherapies in cancer and other immune disorders

Curr Opin Immunol. 2019 Aug:59:79-87. doi: 10.1016/j.coi.2019.03.007. Epub 2019 May 6.

Authors

Camillia S Azimi¹, Qizhi Tang², Kole T Roybal³, Jeffrey A Bluestone⁴

Affiliations

¹ Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
² UCSF Diabetes Center, University of California, San Francisco, San Francisco, CA, USA; Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
³ Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. Electronic address: [email protected].
⁴ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; UCSF Diabetes Center, University of California, San Francisco, San Francisco, CA, USA. Electronic address: [email protected].

PMID: 31071513
DOI: 10.1016/j.coi.2019.03.007

Abstract

T lymphocyte and other cell therapies have the potential to transform how we treat cancers and other diseases that have few therapeutic options. Here, we review the current progress in engineered T cell therapies and look to the future of what will establish cell therapy as the next pillar of medicine. The tools of synthetic biology along with fundamental knowledge in cell biology and immunology have enabled the development of approaches to engineer cells with enhanced capacity to recognize and treat disease safely and effectively. This along with new modes of engineering cells with CRISPR and strategies to make universal 'off-the-shelf' cell therapies will provide more rapid, flexible, and cheaper translation to the clinic.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Autoimmunity
Bioengineering
Cancer Vaccines / immunology*
Clustered Regularly Interspaced Short Palindromic Repeats
Humans
Immune System Diseases / immunology
Immune System Diseases / therapy*
Immunotherapy, Adoptive / methods*
Neoplasms / immunology
Neoplasms / therapy*
T-Lymphocytes / immunology*
T-Lymphocytes / transplantation

Substances

Cancer Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding